Ireland - English - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - valsartan; hydrochlorothiazide - film-coated tablet - 80/12.5 mg/mg - angiotensin ii antagonists and diuretics; valsartan and diuretics

Ireland - English - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - valsartan; hydrochlorothiazide - film-coated tablet - 160/25 mg/mg - angiotensin ii antagonists and diuretics; valsartan and diuretics

Ireland - English - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - valsartan; hydrochlorothiazide - film-coated tablet - 160/12.5 mg/mg - angiotensin ii antagonists and diuretics; valsartan and diuretics

Ireland - English - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - valsartan hydrochlorothiazide - film coated tablet - 320/25 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - valsartan hydrochlorothiazide - film coated tablet - 320/12.5 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - valsartan; hydrochlorothiazide - film-coated tablet - 160/12.5 mg/mg - angiotensin ii antagonists and diuretics; valsartan and diuretics

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - valsartan; hydrochlorothiazide - film-coated tablet - 160/25 mg/mg - angiotensin ii antagonists and diuretics; valsartan and diuretics

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - valsartan; hydrochlorothiazide - film-coated tablet - 80/12.5 mg/mg - angiotensin ii antagonists and diuretics; valsartan and diuretics

United States - English - NLM (National Library of Medicine)

actavis pharma, inc. - valsartan (unii: 80m03yxj7i) (valsartan - unii:80m03yxj7i), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - valsartan 80 mg - valsartan and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including hydrochlorothiazide and the arb class to which valsartan principally belongs. there are no controlled trials demonstrating risk reduction with valsartan and hydrochlorothiazide tablets. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s j

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

actavis uk ltd - valsartan; hydrochlorothiazide - tablet - 80mg ; 12.5mg